<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002215</url>
  </required_header>
  <id_info>
    <org_study_id>292A</org_study_id>
    <secondary_id>MKC-303</secondary_id>
    <nct_id>NCT00002215</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive</brief_title>
  <official_title>A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Triangle Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To compare the proportion of patients whose plasma HIV-1 RNA level falls and remains below&#xD;
      the limit of quantification by the Roche Amplicor Monitor (400 copies/ml)[AS PER AMENDMENT&#xD;
      8/4/98: 50 copies/ml] between weeks 0 and 24. To determine the short-term safety and&#xD;
      tolerability of MKC-442 plus nelfinavir (Viracept) plus dual nucleoside analogs. To determine&#xD;
      the time to viral failure and time to tolerability failure through Week 48 of therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this randomized, placebo-controlled study, patients are allowed to switch at entry to d4T&#xD;
      plus 3TC or d4T plus ddI based on investigator and patient preference. Patients are&#xD;
      stratified based on the number of nucleoside reverse transcriptase inhibitor (NRTI)&#xD;
      treatments that are changed at entry and on screening HIV-1 RNA (obtained within 30 days of&#xD;
      entry) as follows: switched 1 NRTI and 10,000-50,000 copies/ml vs switched 1 NRTI and greater&#xD;
      than 50,000 copies/ml vs switched 2 NRTIs and 10,000-50,000 copies/ml vs switched 2 NRTIs and&#xD;
      greater than 50,000 copies/ml. Patients are randomized within each of these strata to 1 of&#xD;
      the following treatment arms:&#xD;
&#xD;
      Arm 1: MKC-442 placebo plus nelfinavir. Arm 2: MKC-442 plus nelfinavir. Arm 3: MKC-442 plus&#xD;
      nelfinavir (higher dose). Treatment is administered for 48 weeks. Patients who are considered&#xD;
      virologic successes at Week 48 may continue to receive MKC-442 at the discretion of the&#xD;
      investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emivirine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
        At least 1 different nucleoside analog, e.g., 3TC, d4T, or ddI (excluding zidovudine).&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Chemoprophylaxis for Pneumocystis carinii pneumonia.&#xD;
&#xD;
          -  Short courses (less than 21 days) of acyclovir for acute treatment.&#xD;
&#xD;
          -  Recombinant erythropoietin or G-CSF for Grade 3 or greater anemia and neutropenia,&#xD;
             respectively.&#xD;
&#xD;
          -  Allowed only with caution and close patient monitoring:&#xD;
&#xD;
          -  Ketoconazole, fluconazole, itraconazole, and grapefruit juice.&#xD;
&#xD;
          -  Medications metabolized by cytochrome P450.&#xD;
&#xD;
          -  Oral contraceptives, contraceptive implants such as Norplant, or injection-type&#xD;
             contraceptives such as Depo-Provera only if not sole method of contraception.&#xD;
&#xD;
        Patients may have:&#xD;
&#xD;
          -  HIV-1 RNA greater than 10,000.&#xD;
&#xD;
          -  No active AIDS-defining illnesses.&#xD;
&#xD;
          -  Prior experience with 2 nucleoside analogues and able to switch to at least 1&#xD;
             different non-nucleoside analog, e.g., lamivudine (3TC), stavudine (d4T), or&#xD;
             didanosine (ddI) with HIV-1 RNA 10,000 copies/ml or less. [AS PER:&#xD;
&#xD;
          -  8/4/98 AMENDMENT].&#xD;
&#xD;
          -  [AS PER AMENDMENT 8/4/98:&#xD;
&#xD;
          -  Nucleoside analog-naive patients must have HIV-1 RNA greater than 50,000 copies/ml.].&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        Treatment with 2 nucleoside analogs. Note:&#xD;
&#xD;
          -  able to switch to at least 1 different nucleoside analog e.g., lamivudine (3TC),&#xD;
             stavudine (d4T), or didanosine (ddI), while on study [AS PER AMENDMENT 8/4/98].&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with any of the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Active AIDS-defining illnesses.&#xD;
&#xD;
          -  Malabsorption syndrome or severe chronic diarrhea within 30 days of entry, or&#xD;
             inability to consume adequate oral intake due to chronic nausea, emesis, or abdominal&#xD;
             or esophageal discomfort. [AS PER AMENDMENT 8/4/98].&#xD;
&#xD;
          -  Inadequately controlled seizure disorder [AS PER AMENDMENT 8/4/98].&#xD;
&#xD;
          -  Any intercurrent illness that could affect viral load determination [AS PER AMENDMENT&#xD;
             8/4/98].&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Zidovudine.&#xD;
&#xD;
          -  Immunomodulators (e.g., systemic corticosteroids, interleukin-2, or interferons). [AS&#xD;
             PER AMENDMENT 8/4/98].&#xD;
&#xD;
          -  Rifampin, rifabutin, phenobarbital, and hydantoin.&#xD;
&#xD;
          -  Amiodarone, quinidine, astemizole, terfenadine, ergot derivatives, midazolam,&#xD;
             triazolam, and cisapride.&#xD;
&#xD;
          -  Neurotoxic agents (e.g., vincristine, thalidomide). [AS PER AMENDMENT 8/4/98].&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of acute or chronic pancreatitis.&#xD;
&#xD;
          -  History of &gt; grade 2 peripheral neuropathy.&#xD;
&#xD;
          -  Patients with an acute and clinically significant medical event within 30 days of&#xD;
             screening.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Protease inhibitors.&#xD;
&#xD;
          -  Non-nucleoside reverse transcriptase inhibitors.&#xD;
&#xD;
        Excluded within 30 days of study drug administration:&#xD;
&#xD;
          -  Immunomodulators (e.g., systemic corticosteroids, interleukin-2, or interferons). [AS&#xD;
             PER AMENDMENT 8/4/98].&#xD;
&#xD;
          -  Rifampin, rifabutin, phenobarbital, and hydantoin.&#xD;
&#xD;
          -  Amiodarone, quinidine, astemizole, terfenadine, ergot derivatives, midazolam,&#xD;
             triazolam, and cisapride.&#xD;
&#xD;
          -  Immunotherapeutic vaccines.&#xD;
&#xD;
          -  Cytotoxic chemotherapeutic agents [AS PER AMENDMENT 8/4/98].&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 30 days of study drug administration:&#xD;
&#xD;
        Radiation therapy [AS PER AMENDMENT 8/4/98].&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Current alcohol or illicit drug use that, in the opinion of the investigator, may interfere&#xD;
        with ability of patient to comply with dosing schedule and protocol evaluations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anderson Clinical Research</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>RNA, Viral</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Viral Load</keyword>
  <keyword>Nelfinavir</keyword>
  <keyword>Uracil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nelfinavir</mesh_term>
    <mesh_term>Emivirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

